Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by nopooon Jan 17, 2013 11:53pm
263 Views
Post# 20854663

Golden Opportunity Lies in the Details

Golden Opportunity Lies in the Details

Richard (Rick) Mills
Ahead of the Herd

As a general rule, the most successful man in life is the man who has the best information

On January 14th 2013, Alamos Gold Inc. announced it had acquired 23,507,283 Aurizon shares as a result of share purchase agreements between Alamos and certain shareholders of Aurizon. The 23,507,283 shares acquired represent approximately 14.3% of the issued and outstanding Aurizon shares.

Alamos also announced it had commenced a formal offer to acquire the rest of the issued and outstanding Aurizon Shares.

Aurizon will produce 127,000 ounces of gold at cash costs of $719/oz in 2013, ramping up to 153,000 oz in 2014 at estimated cash costs of $696/oz.

Alamos is trying to buy Aurizon for Casa Berardi and Joanna.

Aurizon’s Casa Berardi mine currently hosts 1.5 million ounces of reserves at a grade of 5.3 g/t, and 1.5 million ounces in measured and indicated resources at a grade of 4.3 g/t.

The Joanna project is Aurizon's 100 percent owned primary development project located in the Cadillac Larder Lake Break, between the towns of Rouyn-Noranda and Cadillac in Quebec. The property currently hosts 1.7 million ounces in reserves at a grade of 1.3 g/t and 0.9 million ounces in measured and indicated resources at a grade of 1.3 g/t.

While Aurizon has other projects on the go one in particular stands out - the option/JV deal between Aurizon and NioGold Mining Corporation (TSX-V: NOX).

read more https://aheadoftheherd.com/Newsletter/2013/Golden-Opportunity-Lies-in-the-Details.html

<< Previous
Bullboard Posts
Next >>